Publications

Schildknecht A, Brauer S, Brenner C, Lahl K, Schild HJ, Sparwasser T, Probst HC, van den Broek M. FoxP3+ regulatory T cells essentially contribute to peripheral CD8+ T cell tolerance induced by steady-state dendritic cells. 2010. Proc. Natl. Acad. Sci. USA 107:199-203.

Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S, van den Broek M, Radbruch A, Lévy F, Lambert PH, Siegrist CA, Restifo NP, Löhning M, Ochsenbein AF, Nabel GJ, Pinschewer DD. 2010. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med.16:339-345.

Walter A, Barysch MJ, Behnke S, Dziunycz P, Schmid B, Gnjatic S, Kristiansen G, Moch H,Knuth A, Dummer R, van den Broek M. Cancer testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. 2010. Clin. Cancer Res. 16:3562-3570.

van den Broek M, von Boehmer L, Knuth A. 2010. Developments in cancer immunotherapy. Dig. Dis. 28:51-56

Nuber N, Curioni A, Matter C, Soldini D, Tiercy JM, von Boehmer L, Dummer R, Knuth A, van den Broek M. 2010. Fine analysis of spontaneous MAGE-C1/CT7 specific immunity in melanoma patients. Proc. Natl. Acad. Sci. USA 107:15187-15192.

Moebius J, van den Broek M, Groettrup M, Basler M. 2010. Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. Eur. J. Immunol. 40:3439-3449.

Peters R. Wolf M, van den Broek M, Nuvolone M, Dannenmann S, Stieger B, Rapold R, Konrad D, Rubin A, Bertino JR, Aguzzi A, Heikenwalder M, Knuth A. 2010. Efficient Generation of Multipotent Mesenchymal Stem Cells from Umbilical Cord Blood in Stroma-Free Liquid Culture. PLoS ONE 5:215689.

Civenni G, Walter A, Kobert N, Mihic-Probst D, Belloni B, Seifert B, Moch H, Dummer R, van den Broek M, Sommer L. 2011. CD271-positive melanoma stem cells displaying neural crest stem cell features are associated with poor prognosis. Cancer Research, 71:3098-3109.

Curioni-Fontecedro A, Nuber N, Mihic-Probst D, Seifert B, Soldini D, Dummer R, Knuth A, van den Broek M, Moch H. 2011. Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. PLoS ONE 6:e21418.

von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T, Sulser T, Jungbluth A, Old L, Kristiansen G, van den Broek M, Moch H, Knuth A, Wild P. 2011. MAGE-C2/CT10 protein expression is an independent predictor of recurrence of prostate cancer. PLoS ONE 6:e21366.

Luethy A, Stenner F, Lohri C, Muller C, Samaras P, Steiner R, van den Broek M, Mischo A, Renner C, Knuth A, Ruegg C, Wenger RH, Zweifel M. 2011. Autologous Stem Cell Transplantation: Leukapheresis Product has Anti-angiogenic Effects In Vivo Correlating with Neutrophil-derived VEGFR1. Anticancer Res. 31:3115-24.

Sharma A, Bode B, Wenger RH, Lehmann K, Sartor iAA, Moch H, Knuth A, von Boehmer L, van den Broek M. 2011. g-Radiation Enhances Immunogenicity of Cancer Cells by Increasing the Expression of Cancer-Testis Antigens in vitro and in vivo. PLoS ONE, e28217.

Audigé A, Hofer U, Dittmer U, van den Broek M, Speck RF. 2011. Evaluation of the immunomodulatory and antiviral effects of the cytokine combination IFN-a and IL-7 in the lymphocytic choriomeningitis virus and Friend retrovirus mouse infection models. Viral Immunol. 24(5):375-85.

Von Boehmer L, Draenert A, Jungraithmayr W, Inci I, Niklaus S, Boehler A, Hofer M, Stahel R, Soltermann A, van den Broek M, Weder W, Knuth A. 2012. Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. Lung Cancer. 76:118-122.

Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, Schwendener R, Behnke S, Prischy M, Knuth A, van den Broek M. 2012. Radiotherapy promotes tumor-specific effector CD8+ T cells via DC activation. J.Immunol. 189:558-566.

Schliehe C, Bitzer A, van den BroekM, and Groettrup M. 2012. Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo. J. Virol. 86:9782-9793

Gupta A, Sharma A, von Boehmer L, Surace L, Knuth A, van den Broek M. 2012. Radiotherapy supports protective tumor-specific immunity. OncoImmunology, 1:1610-1611.

Yogev N, Frommer F, Lukas D, Kautz-Neu K, Karram K, Ielo D, von Stebut E, Probst HC, van den Broek M, Riethmacher D, Birnberg T, Blank T, Reizis B, Ko Trn, Wiendl H, Jung S, Prinz M, Kurschus F, Waisman A. 2012. Dendritic Cells Ameliorate Autoimmunity in the CNS by Controlling the Homeostasis of PD-1 Receptor+ Regulatory T Cells. Immunity 37:264-275.

Fischer E, Chaitanya K, Wüest T, Wadle A, Scott AM, van den Broek M, Schibli R, Bauer S, Renner C. 2012. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin Cancer Res., 15:6208-6218.

Gupta A, Nuber N, Esslinger E, Wittenbrink M, Treder M, Landshammer A, NoguchiT, Kelly M, Gnjatic S, Ritter E, von Boehmer L, Nishikawa H, Shiku H, Old L, Ritter G, Knuth A, van den Broek M. 2013. A novel human-derived monoclonal antibody against NY-ESO-1 improves the efficacy of chemotherapy. Cancer Immunity, 13:3-11.

Walter A, Schäfer M, Matter C, Urosevic-Maiwald M,Belloni B, Schönewolf N, Cecconi V, Kulig P, Dummer R, Bloch W, Werner S, Beer HD, Knuth A, van den Broek M. 2013. Aldara activates two independent immune defense pathways. Nat. Commun. 4:1560 doi: 10.1038/ncomms2566.

Braumüller H, Wieder T, Fischer S, Brenner E, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M,Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, van den Broek M, Häring HU, Handgretinger R, Quintanilla-Martinez L, Fend F, Schaller M, Schulze-Osthoff K, Röcken M. 2013. TH1 Cell Cytokines Drive Cancer into Senescence. Nature, 494:361-365.

Dannenmann S, Thielicke J, Stöckli M, Matter C, von Boehmer L, Cecconi V, Hermanns T, Hefermehl L, Schraml P, Moch H, Knuth A, van den Broek M. 2013. Myeloid cells promote progression of clear cell renal cell carcinoma. OncoImmunology, 2: eLocation ID: e23429.

von Boehmer L, Landshammer A, Bode P, Nuber N, Ritter G, Old L, Moch H, Jäger E, Knuth A, van den Broek M. 2013. NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. Cancer Immunity 13:12-18.

SharmaA, BodeB, Studer G, MochH, OkoniewskiM, KnuthA, von BoehmerL, van den Broek M. 2013. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. Clin. Cancer Res. 19:4843-4853.

Dannenmann S, ­­Hermanns T, Bransi A, von Boehmer L, Matter C, Stevanovic S, Schraml P, Moch H, Knuth A, van den Broek M. 2013. Spontaneous peripheral T cell responses towards the tumor-associated antigen Cyclin D1 in patients with clear cell renal cell carcinoma. Cancer Immunology Res. 1:288-295.

Schuberth P, Hagedorn C, Jensen S, Gulati P, van den Broek M, Mischo A, Soltermann A, Jüngel A, Maaroquin Belaunzaran O, Stahel R, Renner C, Petrausch U. 2013. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J. Transl. Med. 11:187-197.

Nuber N, Curioni-Fontecedro A, Dannenmann SR, Matter C, von Boehmer L, Atanakovic D, Knuth A, van den Broek M. 2013. MAGE-C1/CT7 spontaneously triggers a CD4+ T-cell response in multiple myeloma patients. Leukemia 27: 1767-1769.

Jakka G, Schuberth P, Thiel M, Held G, Stenner F, van den Broek M, Renner C, Mischo A, Petrausch U. 2013. Antigen-specific in vitro expansion of functional redirected NY-ESI-1-specific human CD8+ T cells in a cell-free system. Anticancer Res. 33:4189-4201.

Lohri C, Hutzli Schaltegger C, van den Broek M, Wenger R, Ruegg C, Fink D, Fehr M, Knuth A, Zweifel M. 2014. Neutrophil expression of ICAM1, CXCR1, and VEGFR1 in patients with breast cancer before and after adjuvant chemotherapy. Anticancer Res. 34:4693-4700.

Ruf M, Mittmann C, Hartmann A, Hermanns T, Poyet C, van den Broek M, Sulser T, Moch H, Schraml P. 2015. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma. Clin. Cancer Res. 21:890-898.

Surace L, Lysenko V, Fontana AO, Cecconi V, Janssen H, Bicvic A, Okoniewski M, Pruschy M, Dummer R, Neefjes J, Knuth A, Gupta A, van den Broek M. 2015. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. Immunity 42:767-777.

Marroquin Belaunzaran O, Kleber S, Schauer S, Hausmann M, Nicholls F, van den Broek M, Payeli S, Ciurea a, Milling S, Stenner F, Shaw J, Kollnberger S, Bowness P, Petrausch U, Renner C. 2015. HLA-B27-homodimer-specific antibody modulates the expansion of pro-inflammatory T-cells in HLA-B27 transgenic rats. PLOS ONE DOI:10.1371/journal.pone.0130811.

Bransi A, Salgado O, Beffinger M, Milo K, Silina K, Yagita H, Becher B, Knuth A, van den Broek M. 2015. Rational combination of immunotherapy with clinical efficacy in mice with advanced cancer. Cancer Immunology Res. 3:1279-1288.

Surace L, Scheifinger N, Gupta A, van den Broek M. 2015. Radiotherapy supports tumor-specific immunity by acute inflammation. Oncoimmunology, DOI: 10.1080/2162402X.2015.1060391.

Surace L, Guckenberger M, van den Broek M. 2015. Radiation holidays stimulate tumor immunity. Oncotarget 6:15716-15717.